Replies to post #250300 on Avid Bioservices Inc (CDMO)

[biopharm]

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.
..
..
Next up would be Norm Letvin:

Normal L. Letvin:
http://patents.justia.com/inventor/norman-l-letvin

Andrew Parsa:
http://www.freshpatents.com/Andrew-T-Parsa-San-Francisco-invdxa.php

... there is a chain of posts attached to this... but again, Andrew Parsa knew very well of TIM-3 and in case you forgot-- > its a receptor of Phosphatidylserine

TIM-3 is a receptor for phosphatidylserine and allelic variants differentially mediate uptake of apoptotic cells
Xia Bu,1Angela Ballesterous,2Yee-Ling Chim,3Cesar Santiago,2Hyun-Hee Lee,3Dale Umetsu,3Jose Casasnovas,2Rosemarie DeKruyff,3 and Gordon Freeman1

http://www.jimmunol.org/cgi/content/meeting_abstract/184/1_MeetingAbstracts/130.41

Continuously supported by the NIH since 2002, Parsa’s research on brain tumor immunology has provided landmark insights, including the identification of a novel link between oncogenesis and immune-resistance in brain tumors. He is currently the study chair for the largest randomized brain tumor vaccine trial ever to be funded by the National Cancer Institute.

http://news.feinberg.northwestern.edu/2013/02/parsa_chair/

After becoming chair of neurosurgery at Northwestern University’s Feinberg School of Medicine in 2013, he continued to interact with many of us in the department and remained a member of our NIH SPORE in brain cancer. Our heartfelt condolences go out to his family at this time. Dr. Parsa is survived by his wife, Charlotte Shum, a Northwestern associate professor of orthopedic surgery, and their three children: Julia, Micheline and Ismail.

https://www.ucsf.edu/news/2015/04/125371/remembering-andy-parsa

-------------------------------------------------------------

Interesting Immunotherapy Conference back in 2012

some names of interest:

Dr. Jedd Wolchok - keynote speaker

ex-NBC News Chief Robert Bazell - left NBC after 38 years now at Yale @ Department of Molecular, Cellular and Developmental Biology

Dr. Andrew T. Parsa - suddenly passes away - Dr. Parsa? ??moved to? the Chicago area when? he became chair of Neurological Surgery at Northwestern University’s Feinberg School of Medicine ?in 2013 at the young age of 46.
http://www.columbianeurosurgery.org/2015/04/remembering-columbia-neurosurgery-alum-andrew-parsa-md-phd/

Harnessing the body’s immune system to kill brain tumors is a potentially powerful treatment strategy,” says Dr. Bruce. “This paper describes our experience with a novel vaccine that proved to be effective in patients whose glioblastoma had grown back after standard treatment with radiation and chemotherapy. The vaccine was developed by Dr. Andy Parsa, who was one of our former residents at Columbia [2002]. We collaborated with him on this experimental trial and are excited about moving forward with a plan to treat more patients.”
http://www.columbianeurosurgery.org/2014/01/dr-bruce-harnessing-bodys-immune-system-kill-brain-tumors/

Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
http://www.ncbi.nlm.nih.gov/pubmed/24335700 (Crane worked on this with Parsa)

Significant financial challenges, similar to those facing OncoVaxR, have been preventing plans for an international, phase III, double-blind, randomized, placebo-controlled trial to secure regulatory approval. Lastly, Prophage™ (vitespen; formerly HSPPC-96) is an autologous tumor cell derived heat shock protein vaccine that has been tested in Phase III studies in two populations: Stage IV melanoma and renal cell carcinoma in the adjuvant setting.29,30 While both of these studies missed their primary endpoints, retrospective analysis suggested that patients with earlier stage disease and patients who received a greater number of vaccinations may have experienced benefit, hypotheses that require prospective validation.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189545/

Courtney Crane - on patents with Dr. Andrew Parsa
http://www.pcrf-kids.org/site/c.bjJULdNRJkL4H/b.9358055/k.BAB1/Dr_Courtney_Crane.htm

Dr. Susan Slovin - MSK

James Gulley - NCI

David Sable, M.D. - interesting that Sable/Gulley/Slovin and Charles Duncan all sat on a panel and seems like so many ties in this crowd
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116563424

Joseph Pantginis, Ph.D. - ROTH Capital Partners and you should know Peregrine analyst:
http://ir.peregrineinc.com/analysts.cfm

Stelios Papadopoulos, - Chair BOD co-founder Exelixis ... where Peregrine KOL Bruce Chabner has ties/shares...etc

Michail Papamichail - St. Savas Cancer Hospital(GR) ties/researches with Sonia Perez who has ties to Peregrine Nikoletta

Sonia Perez - St. Savas Cancer Hospital - ties to Nikoletta

Col. George E. Peoples - more ties to the above... see below all worked together...

Sonia A. Perez PhD 1,
Eric von Hofe PhD 2,
Nikoletta L. Kallinteris MSCE 2,
Angelos D. Gritzapis PhD 1,
George E. Peoples MD 3,
Michael Papamichail MD, PhD 1,
Constantin N. Baxevanis PhD 1,

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94495465


https://www.regonline.com/custImages/320000/323689/CancerImmunotherapyConf_2012_brochure_final_LR.pdf